Iron chelation therapy for patients with sickle cell disease and iron overload.
Inati
Adlette
A
Division of Pediatric Hematology and Oncology, Children's Centre for Cancer and Blood Diseases, Rafik Hariri University Hospital, Beirut, Lebanon. adlette.inati@lau.edu.lb
Khoriaty
Evelyne
E
Musallam
Khaled M
KM
Taher
Ali T
AT
D000284:Administration, Oral; D000755:Anemia, Sickle Cell / Q000150:complications* / Q000378:metabolism / Q000628:therapy; D001565:Benzoates / Q000008:administration & dosage / Q000627:therapeutic use; D015913:Chelation Therapy / Q000523:psychology; D002648:Child; D000077588:Deferasirox; D000077543:Deferiprone; D003676:Deferoxamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016903:Drug Monitoring; D017707:Erythrocyte Transfusion / Q000009:adverse effects*; D006801:Humans; D007260:Infusion Pumps / Q000523:psychology; D055104:Infusions, Subcutaneous; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019190:Iron Overload / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D010146:Pain / Q000209:etiology; D010349:Patient Compliance; D011728:Pyridones / Q000008:administration & dosage / Q000627:therapeutic use; D012678:Sensation Disorders / Q000139:chemically induced; D012934:Social Isolation; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use; D055815:Young Adult; D015032:Zinc / Q000172:deficiency
D001565:Benzoates; D007502:Iron Chelating Agents; D011728:Pyridones; D014230:Triazoles; D000077543:Deferiprone; D003676:Deferoxamine; D015032:Zinc; D000077588:Deferasirox